Changes in symptoms and symptom impact associated with

CRSwNP observed with DUPIXENT® and placebo

DUPIXENT® significantly decreased SNOT-22 score from baseline vs. placebo + INCS at week 24 and week 521,3

Line graph showing the LS mean change from baseline in SNOT-22 scores for DUPIXENT and placebo. The x-axis ranges from Week 0 to Week 52. There are 150 patients in the DUPIXENT arm and 153 patients in the placebo arm. At Week 52, patients in the DUPIXENT arm experienced a mean reduction of 29.84 in SNOT-22 score (from a baseline score of 50.16) versus a mean reduction of 8.88 in the placebo group (from a baseline score of 53.48). There was a 59% improvement for DUPIXENT versus a 17% improvement for placebo at week 52 with an LS mean difference of -20.96 and a 95% confidence interval of -25.03 to -16.89.

59% improvement vs. 17% improvement at week 52 (LSM difference -20.96; 95% CI -25.03, -16.89) with DUPIXENT® (-29.84 from baseline score 50.16) vs. placebo (-8.88 from baseline score 53.48)

22-item Sino-Nasal Outcome Test (SNOT-22) includes 22 items assessing symptoms and symptom impact associated with CRSwNP. The score ranges from 0 (“no problem”) to 5 (“problem as bad as it can be”).

Connect With a Rep

Have questions about DUPIXENT®? Get answers from a representative.

Sanofi Regeneron Logo

Freedom Support Program

Find out what the Freedom Support Program can bring to your patients and how you can help them access it.



DUPIXENT®, Sanofi and Freedom logos are trademarks of Sanofi, used under license by sanofi-aventis Canada Inc.
REGENERON® is a trademark of Regeneron Pharmaceuticals, Inc. All rights reserved.
© 2023 sanofi-aventis Canada Inc. All rights reserved.

MAT-CA-2300229E
Last updated: 06/2023

paab logo